glp 1 sglt2 Perspectives in weight control in diabetes – inhibitors and GLP-1–glucagon dual agonism Cardiovascular outcome studies in type

Sarafidis P, Ortiz A, Ferro CJ et al

It's not super restrictive

As always, consult your healthcare provider before starting any new supplement

Here we show that GLP-1 RAs are associated with lower risks of mortality, major cardiovascular events (MACEs), and major adverse kidney events (MAKEs) in type 2 diabetes patients with acute kidney disease (AKD)

Orforglipron is the first oral non-peptide GLP-1 receptor agonist in development for FDA approval to treat weight loss, which could make it more convenient than injectable alternatives 1

Its shorter duration of action produces pronounced effects on postprandial glucose through delayed gastric emptying